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Background: Vascular ectasias, including gastric antral vascular ectasia (GAVE) and angiodysplasia, are increasingly
recognized as important sources of gastrointestinal bleeding. This study investigated and compared the efficacies
and outcomes of treatment of upper gastrointestinal (UGI) angiodysplasia and GAVE hemorrhage by endoscopic
argon plasma coagulation (APC).
Methods: From January 2006 to December 2009, 46 patients diagnosed with upper GI bleeding caused by
angiodysplasia or GAVE at a tertiary hospital were recruited into this study. They included 26 males and 20 females
with an average age of 65.6 years (range, 45–90 years). All patients underwent APC for hemostasis during an
endoscopic procedure. Parameters such as underlying co-morbidities, number of endoscopic treatment sessions,
recurrent bleeding, and clinical outcomes during follow-up were analyzed.
Results: The 46 patients with UGI vascular ectasia hemorrhage included 27 patients with angiodysplasia and 19
with GAVE. The patients with angiodysplasia were older than those with GAVE (71.6 ± 10.2 years versus
61.8 ± 11.9 years, P= 0.005). More GAVE patients than angiodysplasia patients had co-existing liver cirrhosis (63.2%
versus 25.9%, P= 0.012). The patients with GAVE had a higher rate of recurrent bleeding (78.9% versus 7.4%,
P< 0.001) and required more treatment sessions to achieve complete hemostasis (2.4 ± 1.4 versus 1.1 ± 0.1,
P< 0.001) than those with angiodysplasia. Univariate analysis demonstrated that age greater than 60 years (odds
ratio (OR) = 8.929, P= 0.003), GAVE (OR = 0.021, P< 0.001), and previous radiation therapy (OR = 11.667, P= 0.032)
were associated with higher rates of recurrent bleeding. Further multivariate analysis revealed that GAVE was the
only independent risk factor for recurrent bleeding after APC treatment (OR = 0.027, P< 0.001).
Conclusion: Endoscopic hemostasis with APC is a safe treatment modality for both angiodysplasia and vascular
ectasia bleeding. The efficacy of APC treatment is greater for angiodysplasia than for vascular ectasia bleeding.
GAVE patients have a higher recurrent bleeding rate and may require multiple treatment sessions for sustained
hemostasis.
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Gastrointestinal vascular ectasia comprises angiodyspla-
sia, gastric antral vascular ectasia (GAVE), and other
forms of telangiectasia related to multisystemic disease,
such as hereditary hemorrhagic telangiectasia, but not
vascular tumors and Dieulafoy’s lesion [1,2]. Angiodys-
plasias are typically discrete, flat or slightly raised,
bright-red lesions 2 to 10 mm in size. GAVE is also
called “watermelon stomach” due to the characteristic
endoscopic findings of linear, friable, red streaks radiat-
ing from the pylorus. GAVE and angiodysplasia are the
most common forms of upper gastrointestinal (UGI)
vascular ectasia. Both are increasingly recognized as im-
portant sources of GI bleeding, accounting for up to 4%
and 3% of cases of upper and lower GI bleeding, respect-
ively [1-4]. The clinical presentation ranges from chronic
gastrointestinal blood loss that leads to chronic anemia
to serious gastrointestinal events such as melena or
hematemesis, which occur especially in patients with
underlying conditions leading to bleeding tendencies,
such as liver cirrhosis, or uremia.
Various thermal modalities are used to treat GI vascu-
lar ectasia, including Neodymium: Yttrium Aluminum
Garnet (Nd: YAG) laser, multipolar electrocoagulation,
and argon plasma coagulation (APC). APC was reported
to be as effective as laser photocoagulation and multi-
polar electrocoagulation and to have advantages over
other non-contact treatments for use in difficult-to-ac-
cess areas [5]. However, few studies have evaluated the
outcomes and prognoses of patients with upper GI vas-
cular ectasia hemorrhage treated with APC. There is also
little information on the efficacy of APC at treating dif-
ferent types of UGI vascular ectasia hemorrhage. In the
current study, we aimed to investigate and compare the
efficacies of endoscopic APC treatment of patients with
different forms of UGI vascular ectasia hemorrhage and
their treatment outcomes.
Methods
From January 2006 to December 2009, we retrospectively
reviewed the medical records of 46 consecutive patients
diagnosed with upper GI bleeding caused by angiodyspla-
sia or GAVE at a university-affiliated tertiary care center.
The patients included 26 males and 20 females with an
average age of 65.6 years (range, 45–90 years). All patients
underwent APC for hemostasis during an endoscopic pro-
cedure. UGI bleeding was diagnosed by (1) clinical signs,
such as hematemesis, coffee ground vomitus, hematoche-
zia, or melena or (2) endoscopic visualization of active
bleeding, adherent blood clots, or coffee-ground material
in the stomach. Patients with (1) possible bleeding lesions
other than vascular ectasia visualized by endoscopy, (2)
treatment by hemostatic modalities other than APC, or
(3) an inability to give informed consent were excluded.The study received approval (No. 99-3027B) from the eth-
ics committee of our institution and conformed to its
guidelines.
Endoscopic treatment
Unless contraindicated, intramuscular hyoscine butylbro-
mide (20 mg) was administered as an antispasmodic agent
approximately 5 minutes before the start of the procedure.
With consent from each patient, APC was performed
through the working channel of the endoscope under dir-
ect visualization by using an electrosurgical generator
(PSD 60; Olympus, Tokyo, Japan) and a 2.3-mm probe
(argon gas flow, 1.0–2.0 L/min; power 40 W). All lesions
were treated until the mucosa became white in appear-
ance after electrocoagulation. The procedures were
repeated for upper GI vascular ectasias if there was recur-
rent GI bleeding (as evidenced by hematemesis or melena)
or a need for further transfusion. Rebleeding was defined
as a new onset of hematemesis, coffee-ground vomitus,
hematochezia, or melena after 24 h of stable vital signs
and hematocrit following endoscopic treatment. After
endoscopic therapy, patients were treated with a proton
pump inhibitor as follows: an 80-mg pantoprazole bolus
was administered intravenously, followed by intravenous
pantoprazole at 80 mg per day until alimentation was pos-
sible and oral pantoprazole at 40 mg per day thereafter.
The patient data collected included underlying co-mor-
bidities, pre-treatment hemoglobin, platelet count, pro-
thrombin and activated partial thrombin times,
endoscopic findings, number of endoscopic treatment ses-
sions, evidence of recurrent bleeding, and clinical out-
come(s) during follow-up.
Statistical analysis
Continuous variables are expressed as the mean and
standard deviation (SD). The continuous variables were
analyzed using the Mann–Whitney U test. Categorical
variables are expressed as totals and as percentages and
were analyzed using the chi-square test or Fisher’s exact
test. Univariate and multivariate logistic regression were
used to analyze the factors related to recurrent bleeding
after APC treatment. A P value less than 0.05 was consid-
ered statistically significant. All statistical analyses were
performed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA).
Results
The diagnosis was angiodysplasia in 27 patients and
GAVE in 19. Seven (25.9%) patients with angiodysplasia
had liver cirrhosis, 6 (22.2%) suffered from end-stage renal
disease, and 1 (3.7%) had hereditary hemorrhagic telangi-
ectasia. Five of 7 cirrhotic patients had hepatoma; 2 were
treated by transarterial embolization via the hepatic artery,
1 by radiation therapy, and 2 by supportive therapy.
Twenty-two of the patients with angiodysplasia had
Table 1 Clinical characteristics, blood-test data, and co-existing diseases in patients with angiodysplasia and gastric
antral vascular ectasia (GAVE)
AngiodysplasiaN= 27 GAVEN=19 P value
Age, years, mean± SD* 71.6 ± 10.2 61.8 ± 11.9 0.005
Gender, M/F 15/12 11/8 0.875
Hemoglobin level (g/L), mean± SD* 84.0 ± 32.0 82.0 ± 21.0 0.971
Platelet count (×109/L), mean± SD* 162.3 ± 84.2 142.1 ± 111.4 0.192
Prothrombin time (sec), mean± SD* 11.1 ± 1.5 11.1 ± 3.3 0.551
Activated partial thromboplastin time (sec), mean± SD* 30.1 ± 5.1 27.0 ± 2.8 0.095
Active blood oozing on endoscopy, n (%) 19 (70.4) 17 (89.5) 0.160
Liver cirrhosis, n (%) 7 (25.9) 12 (63.2) 0.012
End-stage renal disease, n (%) 6 (22.2) 2 (10.5) 0.440
Hepatoma, n (%) 5 (18.5) 7 (36.8) 0.19
}Transarterial embolization, n (%) 2 (7.4) 6 (31.6) 0.051
}Radiation therapy, n (%) 1 (3.7) 5 (26.3) 0.068
* SD: 1 standard deviation
} as previous treatment for hepatoma
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the fundus, 10 with lesions in the body, 7 with lesions in
the antrum, and 3 with lesions at multiple sites, while the
remaining 5 patients had lesions in the duodenum. Con-
comitant gastric and colonic angiodysplasia was found in
1 patient, and both sites were successfully treated with
APC. Of the 19 GAVE patients, 12 (63.2%) had liver cir-
rhosis, while only 2 had end-stage renal diseases. Seven
(36.8%) patients had hepatomas; 6 were treated by transar-
terial embolization via the hepatic artery and 5 by radi-
ation therapy. All of these 5 patients received external
beam radiation therapy after transarterial embolization.
Concurrent portal hypertensive gastropathy (PHG) was
observed in 5 GAVE patients. During endoscopic examin-
ation, active bleeding was found in 70.4% of patients with
angiodysplasia and 89.5% of GAVE patients. The pattern
of active bleeding in all of these cases was oozing. The
clinical characteristics, blood test data endoscopic find-
ings, and co-existing diseases of the 2 disease groups are
shown in Table 1. None of our patients was using anti-
platelet or anti-inflammatory drugs, but 1 of the patients
with angiodysplasia had a history of using aspirin. How-
ever, there was no rebleeding observed after APC treat-
ment in this patient. The patients with angiodysplasiaTable 2 Comparison of the responses of angiodysplasia and G
coagulation
Angiod
Treatment sessions, mean± SD* 1.1 ± 0.1
Recurrent bleeding, n (%) 2 (7.4)
Complete hemostasis and hospital discharge, n (%) 27 (100
Mortality related to bleeding, n (%) 0 (0)
* SD: 1 standard deviationwere older than those with GAVE (71.6 ± 10.2 years versus
61.8± 11.9 years, P= 0.005). A greater proportion of the
GAVE patients than the angiodysplasia patients had co-
existing liver cirrhosis (63.2% versus 25.9%, P=0.012).
Greater proportions of the GAVE patients than the angio-
dysplasia patients had histories of previous transarterial
embolization (31.6% versus 7.4%, P=0.051) and radiation
therapy (26.3% versus 3.7%, P=0.068), although neither of
these differences reached significance.
Initial hemostasis was achieved by APC during endos-
copy in all cases. Recurrent bleeding occurred in 36.9% of
these patients (17/46), including 7.4% (2/27) of those with
angiodysplasia and 78.9% (15/19) of those with GAVE; the
rebleeding was from the previous treatment site in all
cases. The median duration of rebleeding after APC treat-
ment was 14 days (7 to 21 days) in patients with angiodys-
plasia and 23 days (7 to 116 days) in those with GAVE.
There was no complication related to endoscopic treat-
ment in patients with either condition. There was also no
mortality related to GI bleeding in the angiodysplasia
patients, but 3 GAVE patients died of recurrent GI bleed-
ing. All of these 3 patients suffered from co-morbidities
such as concurrent liver cirrhosis and hepatoma, sepsis, or
respiratory failure. As shown in Table 2, APC was moreAVE to treatment with endoscopic argon plasma
ysplasiaN= 27 GAVEN=19 P value
2.4 ± 1.4 <0.001
15 (78.9) <0.001
%) 15 (78.9) 0.024
3 (15.8) 0.064
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discharge in patients with angiodysplasia than in those
with GAVE (100% versus. 78.9%, P=0.024). Patients with
GAVE had a higher rate of rebleeding (78.9% versus 7.4%,
P< 0.001) and required a greater number of treatment
sessions to achieve hemostasis (2.4 ± 1.4 versus 1.1 ± 0.1, P
< 0.001) than those with angiodysplasia. Bleeding-related
mortality was also higher, although not significantly so, in
GAVE patients than in those with angiodysplasia (15.8%
versus 0%, P=0.064). The presence of active oozing was
not significantly associated with a higher rate of mortality
(8.3% versus 0%, P=1.0) or rebleeding (41.7% versus 20%,
P=0.282) after APC treatment. The results of univariate
and multivariate analyses of recurrent bleeding using a lo-
gistic regression model are shown in Table 3. Univariate
analysis demonstrated that age greater than 60 years (odds
ratio (OR)= 8.929, P= 0.003), GAVE (OR=0.021, P
< 0.001), and previous radiation therapy (OR=11.667,
P=0.032) were associated with higher rates of recurrent
bleeding. Further multivariate analysis revealed that only
GAVE was an independent risk factor for recurrent bleed-
ing after APC treatment (OR=0.027, P< 0.001).
Discussion
Angiodysplasia in the GI tract is a vascular lesion the ac-
tual cause of which remains unknown. Many hypotheses
have been advanced in the literature, but most of these
explanations are obscure. GI angiodysplasia has been
reported to be associated with other systemic diseases,
such as aortic valvular diseases, systemic sclerosis, her-
editary hemorrhagic telangiectasis, and end-stage renal
disease [6,7]. Some have speculated that it may be the
result of chronic low-grade venous obstruction second-
ary to increased intramural pressure [8] or local mucosal
hypoxia [9]. Markwick and colleagues [6] reported that
the lesions were mostly multiple and located in theTable 3 Univariate and multivariate analyses of the associatio





Type of vascular ectasia 0.021 0.003–0.131
Acute blood oozing 2.857 0.529–15.384
Liver cirrhosis 3.175 0.913–11.033
ESRD 1.029 0.213–4.973
Hepatoma 2.091 0.547–7.989
Transarterial embolization 3.611 0.739–17.644
Radiation therapy 11.667 1.228–110.803
* Cut-offs: Age: ≥60 or <60 years, gender: male or female, type of vascular ectasia:
cirrhosis: yes or no, ESRD (end-stage renal disease): yes or no, hepatoma: yes or no,proximal part of the stomach, while Weaver and collea-
gues [10] found angiodysplasia most often located at the
junction of the middle to the distal third of the stomach,
similarly to the current study. Likewise, the pathogenesis
of GAVE is also unknown but appears to be related to
liver cirrhosis in most cases. Other disorders are also
associated with GAVE, including chronic renal failure
[11], chronic valvular, ischemic, or hypertensive heart
disease [12], and a variety of autoimmune diseases [13].
The endoscopic appearance of GAVE is unlike that of
angiodysplasia, and Novitsky et al. described 4 different
patterns [7]. The most common of these is antral disease
with classic raised convoluted ridges covered by ectatic
vascular tissue radiating out from the pylorus. Other fea-
tures include radiating flat stripes, scattered multiple
mucosal lesions, and lesions of mixed type. Generally,
linear lesions within the antrum are observed in non-cir-
rhotic patients and diffuse lesions in cirrhotic patients
[14,15]. Regardless of the pattern, bleeding of GAVE
lesions begins with injury by either gastric acid or intra-
luminal food to the mucosal epithelium overlying the
engorged vessels. The severity of bleeding ranges from
minor, but chronic upper GI blood loss to severe melena
and hematemesis that leads to anemia and requires
blood transfusion. In our case series, the patients with
angiodysplasia were older than those with GAVE, al-
though both groups averaged over 60 years of age and
were composed of elderly individuals. The younger age
of GAVE patients may be related to the higher preva-
lence of liver cirrhosis in this group, which in turn can
be explained by the high prevalence rates of Hepatitis B
(10–15%) and Hepatitis C (1–3%) infection in Taiwan
[16-19]. Cirrhosis of the liver was found in 30% to 70%
of patients with GAVE [7,20,21]. Therefore, PHG is usu-
ally present concomitantly with and requires careful dif-
ferentiation from vascular ectasia. In contrast to GAVE,ns of individual parameters with recurrent bleeding in
Multivariate
P OR 95% CI P
0.003 6.796 0.564–70.649 0.109
0.708 _ _ _
<0.001 0.027 0.003–0.247 <0.001
0.222 2.639 0.087–80.114 0.557
0.069 1.562 0.118–20.610 0.775
0.972 _ _ _
0.281 2.214 0.023–211.953 0.733
0.113 1.602 0.007–361.954 0.865
0.032 11.627 0.276–500 0.198
angiodysplasia or GAVE, active blood oozing on endoscopy: yes or no, liver
previous transarterial embolization: yes or no
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ally affects the fundus and corpus of the stomach. How-
ever, GAVE and PHG are considered to be separate
clinical entities because of the frequent presence of
GAVE in the absence of portal hypertension [21]. PHG
is rarely found as the sole cause of significant UGI
bleeding in patients with portal hypertension [22].
Twelve of the GAVE patients in the current study had
liver cirrhosis. Of these, 5 had concomitant PHG, and
none was found to be bleeding from PHG during endo-
scopic examination.
Many endoscopic techniques are used to treat UGI
vascular ectasias, including sclerotherapy, multipolar
electrocoagulation, argon and laser photocoagulation,
and APC [1]. Early publications used mostly Nd: YAG
laser coagulation, which produced acceptable results but
was relatively expensive [23-26]. In the last decade, APC
has been proven to be at least as effective. [5] In pub-
lished series of treatment of GAVE bleeding; the number
of sessions required to achieve hemostasis was lower
when APC was used than when laser or bipolar techni-
ques were used [25-27]. The current study found that
the use of APC to treat both UGI vascular ectasia and
GAVE attained results comparable to those of other
studies, with success rates of near 80% for GAVE [28,29]
and 100% for UGI angiodysplasia [30,31].
APC treatment is characterized by noncontact coagula-
tion, which allows tangential application and thus treat-
ment of the target site in a uniform manner to a depth of
approximately 1 to 3 mm, which is sufficient to coagulate
the superficial blood vessels [32]. Successful APC therapy
leads to whitish coagulation of the mucosa and the dis-
appearance of the underlying vascular structures. The co-
agulation depth of APC depends on the power generator
setting, the distance from the target tissue, and the dur-
ation of the application [33]. Histologically, the tortuous
ectatic vessels of vascular ectasia extend superficially over
the submucosal layer [34]. For this reason, variable power
settings (30–100 W) and flow rates of argon gas (0.8–2
liter/min) have been reported to be safe and effective for
hemostasis of bleeding vascular ectasia [1,5,27-29,32]. To
our knowledge, there are no publications comparing vari-
ous power settings and flow rates for safety and efficacy
for this application. An experienced gastroenterologist can
adjust the distance between the APC probe and the target
lesion and the duration of application to achieve a satisfac-
tory effect at a variety of settings. Therefore, the operator’s
experience and technique are quite crucial to successful
APC treatment.
We observed that the patients with GAVE had a
higher rebleeding rate than those with angiodysplasia
despite no significant differences in platelet count, pro-
thrombin time, activated partial thromboplastin time, or
rates of end-stage renal disease and hepatoma betweenthese 2 groups. On one hand, the prevalence of liver cir-
rhosis (62.3%) in the GAVE patients of the current
study, while consistent with the reported prevalence
rates of 30% to 70% in published series [7,20,27,28], was
higher than in the angiodysplasia patients. The bleeding
tendency associated with liver cirrhosis may have been
responsible for the higher rebleeding rate, and even the
higher mortality rate, in the GAVE group. On the other
hand, the endoscopic appearance of angiodysplasia is
single or multiple discrete red lesions 2 to 10 mm in
size, whereas GAVE is characterized chiefly by ery-
thematous stripes radiating in a spoke-like fashion from
the pylorus to the antrum, mimicking a “watermelon”
appearance. Therefore, the area with potential for bleed-
ing is obviously larger in GAVE patients than in those
with angiodysplasia. The higher rebleeding rate in the
GAVE patients despite careful and thorough treatment
by APC is a therefore a predictable outcome. However,
despite the relatively small size of the lesions, the
rebleeding rate of angiodysplasia after endoscopic treat-
ment is not inconsiderable in some reports; [33] it may
also be higher in uremic patients [32,33,35,36]. There-
fore, this report may have underestimated the rebleeding
rate of angiodysplasia lesions because of the small num-
ber of cases.
Both the Vienna and Asia-Pacific consensuses recom-
mended intravenous high-dose proton-pump inhibitor
(PPI) therapy after successful endoscopic hemostasis of
high-risk bleeding ulcers [37,38]. Nevertheless, many
studies have shown that high-dose PPI treatment does
not further reduce the rate of rebleeding compared with
non-high-dose PPI treatment [39-41]. The optimal dos-
ing of PPIs in these patients remains controversial. How-
ever, maintaining an intragastric pH of >6.0 allows
stabilization of the clot, which stops peptic ulcer bleed-
ing and prevents rebleeding [42-44]. In the case of vas-
cular ectasia bleeding, the use of PPIs could prevent
rebleeding after APC hemostasis and enhance proced-
ure-induced ulcer healing. In this study, we used non-
high-dose PPI treatment and observed an overall
rebleeding rate of 36.9%, including 7.4% of the angiodys-
plasia patients and 78.9% of the GAVE patients. How-
ever, the evidence on the optimal dosing of PPIs
following APC treatment of bleeding vascular ectasia is
limited, and no study gave detailed information on the
dose of PPIs prescribed [27-29]. Therefore, there is need
for further study to clarify this issue.
There was no complication related to APC during en-
doscopy or after treatment in the 74 treatment sessions
of 46 patients of the present study. APC is a non-contact
thermal method of hemostasis that uses argon plasma to
transfer electrical energy to the target tissue. Its charac-
teristics include rapid treatment of multiple or extensive
lesions and decreased depth of penetration. However, all
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thermal hemostasis techniques, such as submucosal em-
physema, superficial ulceration, fibrotic contracture,
stricture, and perforation, can still occur [45]. The per-
foration rate has been reported to range from 0% to 8%
and occurs most frequently when APC is used for abla-
tion of Barrett’s esophagus and palliative ablation for
malignant stenosis [32,45]. The depth of energy penetra-
tion is crucial to the occurrence of perforation after
thermal hemostasis. The relatively superficial coagula-
tion required for treatment of UGI vascular ectasia
should largely avoid this serious complication, making
non-contact APC a safe and effective option
Three GAVE patients in the current study died of re-
current GI bleeding, and all of them suffered from other
co-morbidities, such as concurrent liver cirrhosis and
hepatoma, sepsis, or respiratory failure. Surgical inter-
vention, mainly antrectomy, has been reported for treat-
ment of recurrent bleeding of GAVE lesions [21].
However, surgery is usually reserved for patients who fail
endoscopic therapies and, moreover, are often elderly
with major co-morbid illnesses. The post-operative mor-
bidity in these patients was reported to be up to 23%
with a mortality rate of about 2.5% [46,47]. Therefore, in
consideration of the terminal disease status of these 3
patients, surgery was not considered.
Conclusion
Endoscopic hemostasis with APC is a safe modality for
treatment of both angiodysplasia and vascular ectasia
bleeding. APC is more effective at treating angiodyspla-
sia than at treating vascular ectasia bleeding. GAVE is
associated with a higher rebleeding rate and may require
multiple sessions to achieve sustained hemostasis.
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